ClinicalTrials.gg
CompletedNCT05353166Updated Sep 29, 2026Results posted

REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure

A Phase 2 interventional study of REGN5381 and Matching Placebo in Heart Failure, sponsored by Regeneron Pharmaceuticals. Completed at 1 site in Moldova. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Updated Sep 29, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is researching an experimental drug called REGN5381, further referred to as study drug. The study is focused on adult participants with heart failure that, in the opinion of the study doctor, have a clinical indication for right heart catheterization (RHC). The aim of the study is to evaluate the safety and tolerability of the study drug.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Read the detailed description

Note: Group A has stopped enrolling and Group B will not enroll participants

02

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • New York Heart Association (NYHA) class II/III with symptoms of congestion
  • Elevated Pulmonary Capillary Wedge Pressure
  • Reduced Left Ventricular Ejection Fraction
03

In context

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

This study's enrollment of 59 is below the median of 76 across 4,049 interventional studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. (BMI) between 18 and 35 kg/m\^2, inclusive, rounded to the nearest whole number
  2. Ambulatory participants with (NYHA) class II/III heart failure and at least 1 sign and/or symptom of congestion (eg, dyspnea on exertion, worsening edema, orthopnea, etc.)
  3. (LVEF) ≥20 % and \<50% on echocardiogram (ie, HFrEF participants) within 90 days prior to randomization (only for HFrEF participants in Group A and Group B).
  4. Participants who, in the opinion of the investigator, require a right heart catheterization (not applicable for HFrEF patients not taking sacubitril/valsartan [Group A]).
  5. Left ventricular ejection fraction (LVEF) ≥50% on echocardiogram (ie, HFpEF participants) within 90 days prior to randomization (only for HFpEF participants in Group C)
  6. NT-proBNP >1000 pg/mL or Brain Natriuretic Peptide (active form) (BNP) >300 pg/mL as described in the protocol within 30 days prior to randomization measured by the local laboratory (only for HFrEF participants [Group A and Group B]).
  7. Pulmonary capillary wedge pressure (PCWP) ≥15 mmHg and right artrial pressure (RAP) >5 mmHg on right heart catheterization (RHC) the morning of anticipated study drug dose administration (not applicable for HFrEF participants not taking sacubitril/valsartan [Group A] as described in the protocol).
  8. Systolic blood pressure (SBP) ≥110 mmHg at the screening visit and on day -1
  9. Hematocrit >30% at the screening visit and day -1

Key Exclusion Criteria:

  1. Currently taking IV vasodilators and/or inotropes
  2. Taking sacubitril/valsartan (only for HFrEF and HFpEF participants not taking sacubitril/valsartan [Group A and Group C, respectively])
  3. Taking a phosphodiesterase (PDE) inhibitor (eg, sildenafil), or a soluble guanylate cyclase stimulator (SGCS; ie, vericiguat) within 2 weeks of the screening visit or planning on taking valsartan/sacubitril, a PDE inhibitor, or a SGCS at any point during the study
  4. More than moderate valvular regurgitation/stenosis (ie, moderate-to-severe or severe) on echocardiogram within 90 days prior to randomization
  5. Known infiltrative or hypertrophic cardiomyopathy
  6. Acute coronary syndrome within prior 6 months of randomization
  7. History of cardiac arrest
  8. Cardiac surgery within 3 months of randomization
  9. Pacemaker or defibrillator placement within prior 30 days of randomization
  10. Severe (COPD) (defined as Forced Expiratory Volume in 1st second [] \<50% of predicted or Global Initiative for Chronic Obstructive Lung Disease [GOLD] 3 or 4)
  11. Pulmonary arterial hypertension (World Health Organization [WHO] Group 1) and any medical history at any time of more than moderate pulmonary hypertension (ie, moderate-to-severe, or severe pulmonary hypertension, as described in the protocol
  12. Congenital heart disease (repaired or unrepaired)
  13. Inability to lie flat for cardiac catheterization

Note: Other protocol-defined Inclusion/ Exclusion Criteria apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Group A

    Randomized 1:1; limited to participants with heart failure with reduced ejection fraction (HFrEF) not taking sacubitril/valsartan

    Drug: REGN5381 · Drug: Matching Placebo

  • Experimental
    Group B

    Randomized 1:1; limited to participants with HFrEF taking sacubitril/valsartan

    Drug: REGN5381 · Drug: Matching Placebo

  • Experimental
    Group C

    Randomized 1:1; limited to participants with heart failure with preserved ejection fraction (HFpEF) not taking sacubitril/valsartan

    Drug: REGN5381 · Drug: Matching Placebo

Interventions

  • Single dose administered via IV infusion

  • DrugMatching Placebo

    Single dose administered via IV infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as those adverse events with either initial onset after study drug dose or that represented an exacerbation of a pre-existing condition after the study drug dose.

    Time frame: From first dose (Day 1) up to end of study (Day 126)

Secondary outcomes

  1. Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP)

    PCWP was collected during the right heart catheterization on Day 1.

    Time frame: Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion)

  2. Change From Baseline in Central Venous Pressure (CVP)

    CVP was collected during the right heart catheterization on day 1. For Group A 10mg cohort, the bedside monitor at the site was not compatible with the invasive hemodynamic measurement device, therefore CVP was not captured.

    Time frame: Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)

  3. Change From Baseline in Invasive Cardiac Output (CO)

    CO was collected during the right heart catheterization on day 1. For Group A 10mg cohort, the bedside monitor at the site was not compatible with the invasive hemodynamic measurement device, therefore CO was not captured.

    Time frame: Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)

  4. Change From Baseline in Systemic Vascular Resistance (SVR)

    SVR was derived as follows: \[(Mean Arterial Pressure-Central Venous Pressure)\*80\]/ Invasive Cardiac Output. For the Group A: 10 mg cohort, the site's bedside monitor was not compatible with the invasive hemodynamic measurement device. As a result, CVP was not captured, and SVR could not be calculated due to the missing CVP data.

    Time frame: Baseline, Day 1 (0 hours, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, and 6 hours post end of infusion)

  5. Change From Baseline in Mean Pulmonary Artery Pressure (mPAP)

    mPAP was collected during the right heart catheterization on day 1.

    Time frame: Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)

  6. Change From Baseline in Pulmonary Vascular Resistance (PVR)

    Pulmonary Vascular Resistance was derived as follows: \[(Mean Pulmonary Artery Pressure-Pulmonary Capillary Wedge Pressure)\*80\]/ Invasive Cardiac Output.

    Time frame: Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion)

  7. Change From Baseline in Systolic Blood Pressure (SBP)

    For participants enrolled in Group A cohorts, blood pressure was initially assessed every 2 hours for up to 6 hours after the end of infusion. Following implementation of Protocol Amendment 3, the assessment frequency was increased to hourly only for participants undergoing right heart catheterization (RHC).

    Time frame: Baseline, Day 1 (0, 1, 2, 3, 4, 5, 6, 7, 8 hours post end of infusion), Day 2 to Day 5 every 8 hours, Day 6 first 8 hours, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126

  8. Change From Baseline in Diastolic Blood Pressure (DBP)

    For participants enrolled in Group A cohorts, blood pressure was initially assessed every 2 hours for up to 6 hours after the end of infusion. Following implementation of Protocol Amendment 3, the assessment frequency was increased to hourly only for participants undergoing RHC.

    Time frame: Baseline, Day 1 (0, 1, 2, 3, 4, 5, 6, 7, 8 hours post end of infusion), Day 2 to Day 5 every 8 hours, Day 6 first 8 hours, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126

  9. Change From Baseline in Mean Arterial Pressure (MAP)

    MAP was derived as follows: (1/3\*SBP + 2/3\*DBP).

    Time frame: Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (first 8 hours, second 8 hours, third 8 hours), Day 3 (first 8 hours, second 8 hours, third 8 hours), Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126

  10. Change From Baseline in Pulse Rate (PR)

    For participants enrolled in Group A cohorts, pulse rate was initially assessed every 2 hours for up to 6 hours after the end of infusion. Following implementation of Protocol Amendment 3, the assessment frequency was increased to hourly only for participants undergoing RHC.

    Time frame: Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (first 8 hours, second 8 hours, third 8 hours), Day 3 (first 8 hours, second 8 hours, third 8 hours), Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126

  11. Fold Change From Baseline in N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP)

    NT-proBNP is a clinical biomarker of heart failure. Coefficient of Variation for Fold Change from Baseline was computed as (standard deviation of the natural log-scale of the respective variable) \*100. Fold Change from Baseline is the ratio of Post-Baseline to Baseline, and it is assumed to follow a lognormal distribution. Per the study design, only some participants had a Day 4/Day 5 visit. Therefore, NT-proBNP data were not collected at this time point for all participants.

    Time frame: Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (24 hours post end of infusion), Day 3, Day 4, Day 5, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126

  12. Peak Concentration (Cmax) of REGN5381 in Serum

    Time frame: Up to Day 126

  13. Area Under the Concentration-time Curve From Time Zero to the Time of Last Measurable Concentration (AUClast) of REGN5381 in Serum

    Time frame: Up to Day 126

  14. Number of Participants With Anti-drug Antibodies (ADA)

    The ADA status of each participant was classified as one of the following: * Negative - If all samples were found to be negative in the ADA assay * Pre-existing immunoreactivity - If the baseline sample was positive and all post baseline ADA titers were reported as less than 9-fold the baseline titer value * Treatment-Boosted Response * Treatment-Emergent Response

    Time frame: Baseline up to Day 126

07

Results

Posted Sep 29, 2026

Participant flow

Participant flow — Overall Study
MilestoneGroup A: PlaceboGroup A: REGN5381 10 mgGroup A: REGN5381 30 mgGroup A: REGN5381 100 mgGroup A: REGN5381 300 mgGroup C: PlaceboGroup C: REGN5381 30 mgGroup C: REGN5381 100 mgGroup C: REGN5381 300 mg
Started73364183312
Received study treatment73364183312
Completed73363183312
Not completed000010000
Withdrew: Adverse event000010000

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as those adverse events with either initial onset after study drug dose or that represented an exacerbation of a pre-existing condition after the study drug dose.

Time frame:
From first dose (Day 1) up to end of study (Day 126)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsGroup A: PlaceboGroup A: REGN5381 10 mgGroup A: REGN5381 30 mgGroup A: REGN5381 100 mgGroup A: REGN5381 300 mgGroup C: PlaceboGroup C: REGN5381 30 mgGroup C: REGN5381 100 mgGroup C: REGN5381 300 mg
Number of Participants With Treatment-emergent Adverse Events (TEAEs)111133124
SecondaryChange From Baseline in Pulmonary Capillary Wedge Pressure (PCWP)

PCWP was collected during the right heart catheterization on Day 1.

Time frame:
Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion)
Reported as:
Mean · millimeters of mercury (mmHg)
Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP)
millimeters of mercury (mmHg)Group A: PlaceboGroup A: REGN5381 10 mgGroup A: REGN5381 30 mgGroup A: REGN5381 100 mgGroup A: REGN5381 300 mgGroup C: PlaceboGroup C: REGN5381 30 mgGroup C: REGN5381 100 mgGroup C: REGN5381 300 mg
2 hours post end of infusion-4.7 ± 3.34-5.9 ± 6.00-4.6 ± 1.67-7.1 ± 3.12-5.8 ± 3.80-2.7 ± 1.66-5.9 ± 5.67-7.6 ± 1.50-4.8 ± 1.51
4 hours post end of infusion-5.4 ± 2.49-4.7 ± 6.24-4.7 ± 2.91-6.3 ± 2.09-7.4 ± 4.56-3.2 ± 1.95-5.8 ± 4.88-7.0 ± 0.88-5.4 ± 2.14
6 hours post end of infusion-3.8 ± 2.67-4.6 ± 5.48-3.3 ± 3.93-8.0 ± 1.59-6.7 ± 6.65-3.3 ± 2.32-4.8 ± 4.17-9.3 ± 1.41-7.2 ± 2.22
SecondaryChange From Baseline in Central Venous Pressure (CVP)

CVP was collected during the right heart catheterization on day 1. For Group A 10mg cohort, the bedside monitor at the site was not compatible with the invasive hemodynamic measurement device, therefore CVP was not captured.

Time frame:
Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)
Reported as:
Mean · mmHg
Change From Baseline in Central Venous Pressure (CVP)
mmHgGroup A: PlaceboGroup A: REGN5381 10 mgGroup A: REGN5381 30 mgGroup A: REGN5381 100 mgGroup A: REGN5381 300 mgGroup C: PlaceboGroup C: REGN5381 30 mgGroup C: REGN5381 100 mgGroup C: REGN5381 300 mg
0-1 hour post start of infusion1.7 ± 1.62—-4.6 ± 7.71-0.2 ± 0.43-0.3 ± 0.44-0.3 ± 1.56-0.3 ± 1.82-0.2 ± 0.15-0.6 ± 2.52
1-2 hours post start of infusion1.2 ± 2.07—-4.1 ± 7.960.0 ± 1.08-1.6 ± 1.09-0.9 ± 2.04-1.1 ± 2.58-1.7 ± 1.18-1.6 ± 2.64
2-3 hours post start of infusion-0.7 ± 3.73—-6.0 ± 8.37-0.3 ± 3.26-2.9 ± 1.97-1.8 ± 1.44-1.3 ± 1.41-2.1 ± 1.15-1.7 ± 2.35
3-4 hours post start of infusion-0.3 ± 2.76—-5.5 ± 7.95-1.3 ± 1.03-2.8 ± 1.98-1.4 ± 2.78-3.2 ± 2.15-2.3 ± 2.13-3.3 ± 2.79
4-5 hours post start of infusion-0.5 ± 3.39—-6.7 ± 8.67-1.5 ± 1.40-4.1 ± 3.26-2.2 ± 2.54-4.1 ± 2.80-2.9 ± 1.84-4.3 ± 2.29
5-6 hours post start of infusion-0.7 ± 1.95—-5.7 ± 8.61-2.3 ± 1.57-4.7 ± 3.80-2.7 ± 2.73-3.5 ± 1.24-3.6 ± 1.52-4.4 ± 2.39
6-7 hours post start of infusion0.2 ± 2.23—-5.6 ± 8.92-3.2 ± 2.42-4.6 ± 3.07-3.0 ± 2.48-4.1 ± 2.32-3.3 ± 0.55-5.0 ± 2.82
SecondaryChange From Baseline in Invasive Cardiac Output (CO)

CO was collected during the right heart catheterization on day 1. For Group A 10mg cohort, the bedside monitor at the site was not compatible with the invasive hemodynamic measurement device, therefore CO was not captured.

Time frame:
Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)
Reported as:
Mean · Liters per minute (L/min)
Change From Baseline in Invasive Cardiac Output (CO)
Liters per minute (L/min)Group A: PlaceboGroup A: REGN5381 10 mgGroup A: REGN5381 30 mgGroup A: REGN5381 100 mgGroup A: REGN5381 300 mgGroup C: PlaceboGroup C: REGN5381 30 mgGroup C: REGN5381 100 mgGroup C: REGN5381 300 mg
0-1 hour post start of infusion0.16 ± 0.953—-0.44 ± 1.2580.17 ± 0.6740.27 ± 0.157-0.14 ± 0.547-0.01 ± 0.3940.12 ± 0.260-0.36 ± 0.598
1-2 hours post start of infusion0.29 ± 0.811—-0.57 ± 1.5550.03 ± 0.9420.48 ± 0.8290.05 ± 0.6220.02 ± 0.5520.26 ± 0.255-0.37 ± 0.658
2-3 hours post start of infusion0.00 ± 1.005—-0.64 ± 1.337-0.08 ± 0.8940.31 ± 0.8660.25 ± 0.4040.39 ± 0.7130.09 ± 0.381-0.23 ± 0.849
3-4 hours post start of infusion0.39 ± 0.705—-0.91 ± 1.409-0.53 ± 0.9460.36 ± 1.1110.46 ± 0.8070.84 ± 0.8460.21 ± 0.386-0.08 ± 1.020
4-5 hours post start of infusion0.61 ± 1.120—-1.31 ± 0.444-0.12 ± 1.2140.48 ± 1.2710.75 ± 0.8560.00 ± 1.2570.12 ± 0.482-0.39 ± 1.055
5-6 hours post start of infusion0.18 ± 1.128—-1.06 ± 0.9120.27 ± 1.5500.18 ± 0.9260.55 ± 0.663-0.40 ± 0.9930.01 ± 0.339-0.31 ± 0.970
6-7 hours post start of infusion0.06 ± 1.186—-1.22 ± 0.5300.06 ± 1.140-0.01 ± 1.1820.42 ± 0.7880.14 ± 0.914-0.45 ± 0.575-0.63 ± 1.173
SecondaryChange From Baseline in Systemic Vascular Resistance (SVR)

SVR was derived as follows: \[(Mean Arterial Pressure-Central Venous Pressure)\*80\]/ Invasive Cardiac Output. For the Group A: 10 mg cohort, the site's bedside monitor was not compatible with the invasive hemodynamic measurement device. As a result, CVP was not captured, and SVR could not be calculated due to the missing CVP data.

Time frame:
Baseline, Day 1 (0 hours, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, and 6 hours post end of infusion)
Reported as:
Mean · dynes*second/centimeter^5 (dynes*s/cm^5)
Change From Baseline in Systemic Vascular Resistance (SVR)
dynes*second/centimeter^5 (dynes*s/cm^5)Group A: PlaceboGroup A: REGN5381 10 mgGroup A: REGN5381 30 mgGroup A: REGN5381 100 mgGroup A: REGN5381 300 mgGroup C: PlaceboGroup C: REGN5381 30 mgGroup C: REGN5381 100 mgGroup C: REGN5381 300 mg
0 hours post end of infusion-532.3———-140.4 ± 376.06-47.0 ± 249.478.8 ± 341.15-134.2 ± 37.16110.1 ± 350.02
1 hour post end of infusion-177.8 ± 57.33———-135.8 ± 621.8522.8 ± 281.92-111.9 ± 349.44-98.8 ± 42.21195.3 ± 316.23
2 hours post end of infusion-200.2 ± 393.80—144.4 ± 410.20-111.1 ± 161.6072.2 ± 530.78-48.4 ± 248.87-417.6 ± 436.76-87.6 ± 130.03-31.1 ± 266.34
3 hours post end of infusion-783.1———-8.1 ± 369.55-187.5 ± 320.75-279.4 ± 584.68-176.0 ± 157.6922.2 ± 380.63
4 hours post end of infusion-286.9 ± 426.15—337.1 ± 212.36-92.5 ± 343.8967.0 ± 499.98-204.9 ± 303.79315.9 ± 432.37-175.3 ± 233.77166.1 ± 348.38
5 hours post end of infusion-931.1———56.9 ± 199.05-74.1 ± 263.81-44.3 ± 323.25-89.4 ± 270.01103.2 ± 316.66
6 hours post end of infusion-26.1 ± 514.13—207.5 ± 35.47-273.2 ± 399.00243.2 ± 583.73-58.5 ± 262.84-53.2 ± 211.54-26.3 ± 234.13196.8 ± 369.07
SecondaryChange From Baseline in Mean Pulmonary Artery Pressure (mPAP)

mPAP was collected during the right heart catheterization on day 1.

Time frame:
Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)
Reported as:
Mean · mmHg
Change From Baseline in Mean Pulmonary Artery Pressure (mPAP)
mmHgGroup A: PlaceboGroup A: REGN5381 10 mgGroup A: REGN5381 30 mgGroup A: REGN5381 100 mgGroup A: REGN5381 300 mgGroup C: PlaceboGroup C: REGN5381 30 mgGroup C: REGN5381 100 mgGroup C: REGN5381 300 mg
0-1 hour post start of infusion0.5 ± 1.39-0.3 ± 5.150.3 ± 0.84-2.2 ± 2.52-0.2 ± 1.520.2 ± 1.46-1.4 ± 2.78-0.8 ± 0.04-0.8 ± 1.50
1-2 hours post start of infusion1.1 ± 2.054.2 ± 0.920.6 ± 1.70-2.1 ± 2.09-1.7 ± 2.480.2 ± 2.05-1.9 ± 2.13-2.9 ± 2.04-1.0 ± 1.89
2-3 hours post start of infusion-1.6 ± 1.620.4 ± 4.16-4.0 ± 4.61-2.3 ± 1.76-2.3 ± 1.57-0.4 ± 1.61-2.1 ± 3.94-3.6 ± 3.17-1.8 ± 2.08
3-4 hours post start of infusion-1.4 ± 0.90-4.1 ± 1.27-1.4 ± 1.82-4.5 ± 1.58-2.9 ± 1.49-0.2 ± 2.56-4.3 ± 5.98-5.8 ± 4.69-2.9 ± 2.95
4-5 hours post start of infusion-1.6 ± 2.40-2.1 ± 3.05-7.2 ± 9.51-2.4 ± 4.13-3.9 ± 3.89-1.6 ± 1.56-6.0 ± 5.73-6.4 ± 3.42-4.2 ± 2.10
5-6 hours post start of infusion-1.9 ± 1.55-0.8 ± 2.33-3.0 ± 4.22-5.5 ± 2.08-4.6 ± 5.69-2.3 ± 2.45-5.0 ± 4.53-7.6 ± 6.64-4.6 ± 1.80
6-7 hours post start of infusion-0.4 ± 1.33-0.1 ± 2.66-4.6 ± 8.28-5.5 ± 3.15-4.5 ± 4.40-2.2 ± 2.38-5.7 ± 6.79-3.8 ± 1.45-5.2 ± 2.95
SecondaryChange From Baseline in Pulmonary Vascular Resistance (PVR)

Pulmonary Vascular Resistance was derived as follows: \[(Mean Pulmonary Artery Pressure-Pulmonary Capillary Wedge Pressure)\*80\]/ Invasive Cardiac Output.

Time frame:
Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion)
Reported as:
Mean · dynes*s/cm^5
Change From Baseline in Pulmonary Vascular Resistance (PVR)
dynes*s/cm^5Group A: PlaceboGroup A: REGN5381 10 mgGroup A: REGN5381 30 mgGroup A: REGN5381 100 mgGroup A: REGN5381 300 mgGroup C: PlaceboGroup C: REGN5381 30 mgGroup C: REGN5381 100 mgGroup C: REGN5381 300 mg
2 hours post end of infusion11.5 ± 45.44—72.1 ± 55.4478.2 ± 37.2889.9 ± 96.8931.5 ± 52.1413.5 ± 13.5530.0 ± 68.2659.1 ± 82.64
4 hours post end of infusion15.3 ± 74.84—84.8 ± 53.0564.1 ± 74.11114.4 ± 172.35-2.1 ± 49.6569.1 ± 42.297.5 ± 66.8737.6 ± 46.72
6 hours post end of infusion7.7 ± 95.34—37.7 ± 38.8255.2 ± 70.42147.8 ± 164.45-1.1 ± 51.76-21.4 ± 73.6551.2 ± 35.7668.6 ± 76.60
SecondaryChange From Baseline in Systolic Blood Pressure (SBP)

For participants enrolled in Group A cohorts, blood pressure was initially assessed every 2 hours for up to 6 hours after the end of infusion. Following implementation of Protocol Amendment 3, the assessment frequency was increased to hourly only for participants undergoing right heart catheterization (RHC).

Time frame:
Baseline, Day 1 (0, 1, 2, 3, 4, 5, 6, 7, 8 hours post end of infusion), Day 2 to Day 5 every 8 hours, Day 6 first 8 hours, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
Reported as:
Mean · mmHg
Change From Baseline in Systolic Blood Pressure (SBP)
mmHgGroup A: PlaceboGroup A: REGN5381 10 mgGroup A: REGN5381 30 mgGroup A: REGN5381 100 mgGroup A: REGN5381 300 mgGroup C: PlaceboGroup C: REGN5381 30 mgGroup C: REGN5381 100 mgGroup C: REGN5381 300 mg
Day 1 (0 hours post end of infusion)3.7 ± 11.59——2.0 ± 8.491.5 ± 5.57-0.8 ± 8.831.7 ± 13.61-1.7 ± 4.511.6 ± 9.22
Day 1 (1 hour post end of infusion)4.0 ± 5.29——3.0 ± 1.413.8 ± 9.00-0.5 ± 10.89-1.7 ± 13.65-4.3 ± 5.77-0.6 ± 12.70
Day 1 (2 hours post end of infusion)3.0 ± 11.02-10.3 ± 12.01-7.7 ± 5.51-7.5 ± 5.321.3 ± 8.50-0.6 ± 10.31-13.0 ± 11.79-5.0 ± 6.56-6.7 ± 14.00
Day 1 (3 hours post end of infusion)-5.0 ± 3.46——-5.5 ± 6.362.5 ± 8.50-4.7 ± 8.92-12.7 ± 10.50-12.7 ± 4.16-8.3 ± 16.09
Day 1 (4 hours post end of infusion)-2.3 ± 4.03-9.0 ± 9.64-9.0 ± 13.45-2.3 ± 7.66-0.5 ± 8.35-4.6 ± 10.592.7 ± 2.31-10.3 ± 9.24-7.5 ± 13.91
Day 1 (5 hours post end of infusion)3.0 ± 12.17——-4.0 ± 8.49-6.5 ± 16.42-1.9 ± 10.75-7.7 ± 15.01-6.3 ± 14.05-7.7 ± 13.98
Day 1 (6 hours post end of infusion)-1.3 ± 2.56-7.3 ± 15.04-2.0 ± 6.93-5.7 ± 7.26-7.5 ± 15.61-1.5 ± 11.52-1.7 ± 10.69-5.7 ± 6.43-7.9 ± 13.21
Day 2 (first 8 hours)-6.7 ± 16.33-13.3 ± 2.087.0 ± 20.66-7.2 ± 9.75-8.5 ± 21.19-12.9 ± 15.22-14.7 ± 15.53-8.0 ± 6.93-15.2 ± 14.55
Day 2 (second 8 hours)-20.7 ± 15.40-17.7 ± 8.62-7.0 ± 18.33-11.0 ± 11.78-8.3 ± 25.05-21.8 ± 14.63-15.7 ± 14.05-7.3 ± 5.03-22.3 ± 8.52
Day 2 (third 8 hours)-10.9 ± 11.81-21.7 ± 11.37-4.0 ± 24.27-9.2 ± 11.36-7.5 ± 16.84-13.4 ± 15.27-14.7 ± 9.81-14.3 ± 11.24-11.8 ± 11.09
Day 3 (first 8 hours)-16.1 ± 16.75-18.0 ± 6.24-8.7 ± 9.50-4.8 ± 10.01-7.5 ± 13.23-20.4 ± 14.21-22.3 ± 16.29-18.3 ± 11.55-11.3 ± 11.24
Day 3 (second 8 hours)-11.0 ± 7.26——-3.3 ± 9.29—-15.8 ± 16.88-12.0 ± 13.23-8.7 ± 7.37-19.7 ± 13.45
Day 3 (third 8 hours)-6.8 ± 21.25——-5.3 ± 11.06—-12.1 ± 15.69-6.7 ± 16.04-6.0 ± 3.46-5.6 ± 17.47
Day 4 (first 8 hours)-7.8 ± 14.31——-2.0 ± 17.58-39.0-18.9 ± 15.94-15.7 ± 15.57-12.3 ± 2.08-8.5 ± 13.85
Day 4 (second 8 hours)2.0——0.0 ± 8.49—-16.3 ± 19.67-9.3 ± 18.23-17.5 ± 2.12-9.7 ± 12.49
Day 4 (third 8 hours)-9.0——-4.5 ± 10.61—-12.7 ± 16.84-9.3 ± 13.65-15.0 ± 5.66-9.1 ± 9.17
Day 5 (first 8 hours)-8.0——0.0 ± 21.21—-16.6 ± 16.98-22.3 ± 22.37-20.0 ± 13.00-10.0 ± 11.10
Day 5 (second 8 hours)———-7.0—-6.5 ± 19.09——-17.0 ± 12.73
Day 5 (third 8 hours)———-2.0—-13.0 ± 18.38——-5.0 ± 9.90
Day 6 (first 8 hours)———-6.0—————
Day 8-4.1 ± 15.23-12.0 ± 13.758.3 ± 4.512.8 ± 12.73-13.3 ± 19.86-16.6 ± 17.39-21.7 ± 8.74-16.3 ± 6.43-3.9 ± 12.71
Day 15-7.3 ± 10.48-8.7 ± 17.479.3 ± 6.66-4.8 ± 9.99-8.0 ± 14.11-9.7 ± 15.86-15.7 ± 13.01-12.7 ± 6.81-3.8 ± 10.94
Day 22-9.1 ± 12.08-15.7 ± 17.904.3 ± 7.091.3 ± 16.020.3 ± 26.39-8.8 ± 16.37-9.0 ± 14.11-17.7 ± 10.970.0 ± 12.95
Day 36-14.5 ± 13.84—2.3 ± 11.931.5 ± 13.77-1.0 ± 24.76-12.4 ± 13.88-7.3 ± 13.20-11.3 ± 9.29-4.1 ± 12.84
Day 57-4.2 ± 8.98——1.8 ± 17.79-3.7 ± 25.38-10.4 ± 11.83—-14.0 ± 11.53-1.4 ± 13.69
Day 78-9.8 ± 11.90——-0.5 ± 15.50-10.7 ± 17.56-9.5 ± 12.28—-18.7 ± 7.64-3.5 ± 8.95
Day 99-4.0 ± 14.14———-13.7 ± 29.70-4.0 ± 13.21——-4.3 ± 16.69
Day 126-8.0 ± 15.56———-1.7 ± 10.60-9.8 ± 16.01——-6.0 ± 14.53
SecondaryChange From Baseline in Diastolic Blood Pressure (DBP)

For participants enrolled in Group A cohorts, blood pressure was initially assessed every 2 hours for up to 6 hours after the end of infusion. Following implementation of Protocol Amendment 3, the assessment frequency was increased to hourly only for participants undergoing RHC.

Time frame:
Baseline, Day 1 (0, 1, 2, 3, 4, 5, 6, 7, 8 hours post end of infusion), Day 2 to Day 5 every 8 hours, Day 6 first 8 hours, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
Reported as:
Mean · mmHg
Change From Baseline in Diastolic Blood Pressure (DBP)
mmHgGroup A: PlaceboGroup A: REGN5381 10 mgGroup A: REGN5381 30 mgGroup A: REGN5381 100 mgGroup A: REGN5381 300 mgGroup C: PlaceboGroup C: REGN5381 30 mgGroup C: REGN5381 100 mgGroup C: REGN5381 300 mg
Day 1 (0 hours post end of infusion)0.3 ± 8.08——6.0 ± 5.66-3.3 ± 5.62-1.0 ± 5.780.0 ± 5.20-2.7 ± 4.510.7 ± 6.80
Day 1 (1 hour post end of infusion)1.7 ± 2.89——4.0 ± 2.83-1.8 ± 6.500.8 ± 8.14-1.3 ± 2.31-4.7 ± 4.730.8 ± 4.73
Day 1 (2 hours post end of infusion)0.9 ± 7.90-3.3 ± 6.03-7.7 ± 4.51-8.3 ± 5.28-0.5 ± 5.45-0.8 ± 7.96-9.3 ± 10.50-7.3 ± 6.66-1.2 ± 8.08
Day 1 (3 hours post end of infusion)-4.7 ± 5.69——-4.0 ± 8.49-1.3 ± 6.85-3.1 ± 6.77-6.3 ± 9.61-8.3 ± 1.53-3.8 ± 8.94
Day 1 (4 hours post end of infusion)-3.9 ± 5.21-8.3 ± 5.77-8.0 ± 11.36-2.3 ± 6.56-3.0 ± 4.69-2.7 ± 7.690.0 ± 4.00-7.3 ± 4.04-4.4 ± 8.20
Day 1 (5 hours post end of infusion)0.0 ± 5.00——-2.0 ± 4.24-4.3 ± 6.80-0.6 ± 7.240.0 ± 8.54-5.7 ± 7.02-4.1 ± 9.17
Day 1 (6 hours post end of infusion)-1.3 ± 6.32-7.7 ± 7.51-6.7 ± 13.43-4.8 ± 7.70-5.8 ± 6.501.9 ± 9.101.3 ± 2.89-6.7 ± 4.73-3.3 ± 8.15
Day 2 (first 8 hours)-7.3 ± 7.99-10.7 ± 1.53-0.3 ± 13.58-8.2 ± 6.82-12.8 ± 12.58-7.2 ± 9.85-9.0 ± 9.00-3.3 ± 3.21-9.1 ± 8.02
Day 2 (second 8 hours)-15.3 ± 7.52-18.3 ± 6.35-9.0 ± 13.08-10.7 ± 7.94-13.3 ± 10.84-10.3 ± 10.03-9.7 ± 5.51-5.7 ± 7.02-13.6 ± 8.62
Day 2 (third 8 hours)-9.7 ± 10.89-16.3 ± 7.77-9.0 ± 16.82-8.7 ± 10.27-8.5 ± 8.50-9.3 ± 9.87-11.0 ± 8.19-8.0 ± 6.24-8.2 ± 7.47
Day 3 (first 8 hours)-11.9 ± 11.98-13.7 ± 6.11-13.0 ± 8.54-8.5 ± 4.72-9.8 ± 6.24-11.3 ± 8.78-15.0 ± 15.10-8.7 ± 5.03-5.7 ± 7.40
Day 3 (second 8 hours)-8.3 ± 6.34——-5.3 ± 7.51—-8.6 ± 11.12-14.3 ± 9.07-6.7 ± 4.93-10.9 ± 8.77
Day 3 (third 8 hours)-5.3 ± 12.97——-4.3 ± 11.02—-7.1 ± 8.37-16.3 ± 14.22-5.3 ± 3.06-5.2 ± 11.61
Day 4 (first 8 hours)-6.3 ± 12.53——-6.3 ± 15.63-31.0-8.8 ± 9.01-14.7 ± 4.62-8.3 ± 4.04-6.5 ± 8.15
Day 4 (second 8 hours)-3.0——-1.0 ± 5.66—-8.2 ± 12.28-15.3 ± 14.64-12.0 ± 8.49-6.8 ± 7.29
Day 4 (third 8 hours)-15.0——-4.5 ± 9.19—-6.4 ± 11.54-15.7 ± 9.24-8.0 ± 5.66-7.2 ± 6.94
Day 5 (first 8 hours)2.0——-0.5 ± 19.09—-8.1 ± 10.10-16.0 ± 15.13-11.7 ± 7.51-8.2 ± 7.93
Day 5 (second 8 hours)———-8.0—-6.5 ± 12.02——-11.5 ± 3.54
Day 5 (third 8 hours)———0.0—-9.0 ± 8.49——-7.0 ± 2.83
Day 6 (first 8 hours)———-8.0—————
Day 8-5.6 ± 13.25-7.0 ± 15.72-4.3 ± 2.89-2.7 ± 8.80-12.7 ± 13.87-9.3 ± 10.46-15.7 ± 11.93-9.3 ± 3.51-2.8 ± 7.03
Day 15-7.7 ± 5.68-6.3 ± 13.65-1.3 ± 3.06-5.5 ± 11.15-12.7 ± 6.51-5.2 ± 8.77-10.0 ± 9.64-7.0 ± 6.00-4.8 ± 5.47
Day 22-8.0 ± 7.26-16.3 ± 9.50-2.0 ± 5.29-2.7 ± 7.12-10.7 ± 16.62-3.1 ± 9.29-12.0 ± 9.54-9.7 ± 3.06-3.8 ± 7.59
Day 36-12.3 ± 8.85—-6.7 ± 12.42-1.5 ± 14.29-15.7 ± 20.74-5.3 ± 6.82-10.7 ± 7.37-6.7 ± 5.86-5.1 ± 12.91
Day 57-5.8 ± 7.36——-2.5 ± 15.88-17.0 ± 22.61-4.5 ± 7.02—-6.3 ± 6.43-2.7 ± 5.63
Day 78-5.6 ± 5.77——-6.5 ± 14.24-16.0 ± 13.89-3.3 ± 6.69—-8.3 ± 3.06-5.8 ± 6.94
Day 99-2.0 ± 2.83———-18.0 ± 18.25-0.3 ± 6.20——-3.8 ± 8.50
Day 126-6.0 ± 12.73———-11.7 ± 14.01-3.8 ± 10.82——-4.2 ± 10.79
SecondaryChange From Baseline in Mean Arterial Pressure (MAP)

MAP was derived as follows: (1/3\*SBP + 2/3\*DBP).

Time frame:
Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (first 8 hours, second 8 hours, third 8 hours), Day 3 (first 8 hours, second 8 hours, third 8 hours), Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
Reported as:
Mean · mmHg
Change From Baseline in Mean Arterial Pressure (MAP)
mmHgGroup A: PlaceboGroup A: REGN5381 10 mgGroup A: REGN5381 30 mgGroup A: REGN5381 100 mgGroup A: REGN5381 300 mgGroup C: PlaceboGroup C: REGN5381 30 mgGroup C: REGN5381 100 mgGroup C: REGN5381 300 mg
Day 1 (2 hours post end of infusion)1.5 ± 9.10-5.6 ± 7.13-7.3 ± 2.91-8.4 ± 5.030.0 ± 2.33-0.5 ± 8.64-9.4 ± 11.75-7.8 ± 4.81-3.4 ± 8.69
Day 1 (4 hours post end of infusion)-3.4 ± 4.30-8.8 ± 4.17-8.1 ± 12.08-2.7 ± 6.84-1.9 ± 0.96-3.3 ± 8.272.2 ± 2.34-8.3 ± 5.70-5.4 ± 8.87
Day 1 (6 hours post end of infusion)-1.0 ± 5.04-7.7 ± 11.02-5.0 ± 11.67-5.6 ± 7.96-7.2 ± 7.830.8 ± 9.751.6 ± 5.48-6.7 ± 4.41-5.1 ± 9.01
Day 2 (first 8 hours)-7.4 ± 10.44-12.3 ± 1.201.9 ± 15.60-8.3 ± 6.80-11.6 ± 14.23-8.9 ± 10.93-10.2 ± 10.03-5.4 ± 3.83-11.7 ± 9.31
Day 2 (second 8 hours)-17.0 ± 8.84-18.8 ± 7.24-8.2 ± 15.00-10.8 ± 8.72-10.8 ± 16.01-14.1 ± 9.68-11.4 ± 8.50-6.9 ± 5.83-16.8 ± 8.04
Day 2 (third 8 hours)-10.2 ± 10.90-18.1 ± 7.43-7.7 ± 19.22-8.7 ± 10.39-7.2 ± 10.93-10.5 ± 10.10-10.3 ± 8.41-10.1 ± 7.90-9.8 ± 8.33
Day 3 (first 8 hours)-13.0 ± 12.70-15.6 ± 4.17-11.7 ± 7.62-8.1 ± 5.989.2 ± 8.57-14.0 ± 8.91-16.9 ± 14.54-12.2 ± 6.99-7.7 ± 7.66
Day 3 (second 8 hours)-9.6 ± 6.56——-5.1 ± 6.47—-10.6 ± 12.17-12.3 ± 8.19-7.6 ± 5.54-13.9 ± 9.23
Day 3 (third 8 hours)-5.6 ± 15.57——-4.3 ± 10.49—-8.8 ± 9.95-12.2 ± 13.49-5.8 ± 3.27-4.6 ± 13.09
Day 8-4.3 ± 12.43-9.1 ± 14.83-0.2 ± 3.56-0.9 ± 10.06-12.9 ± 14.00-11.5 ± 12.01-16.9 ± 9.73-12.0 ± 4.26-2.4 ± 7.82
Day 15-7.4 ± 7.15-8.0 ± 14.711.9 ± 3.91-4.9 ± 10.56-11.2 ± 7.38-6.2 ± 10.02-12.9 ± 8.66-9.2 ± 6.74-4.2 ± 5.43
Day 22-8.1 ± 7.78-17.3 ± 10.680.2 ± 5.82-1.4 ± 10.23-7.0 ± 19.01-5.2 ± 10.63-8.7 ± 9.17-12.7 ± 5.46-2.9 ± 7.51
Day 36-13.6 ± 9.41—-3.6 ± 12.73-1.1 ± 12.99-11.7 ± 21.23-7.5 ± 7.78-8.6 ± 7.58-8.0 ± 7.06-5.2 ± 12.01
Day 57-4.7 ± 3.89——-1.4 ± 16.42-12.3 ± 23.69-6.5 ± 7.86—-9.4 ± 7.90-2.0 ± 6.75
Day 78-6.7 ± 6.97——-3.9 ± 13.83-14.0 ± 15.77-5.7 ± 7.66—-11.3 ± 2.03-5.1 ± 6.94
Day 99-3.0 ± 2.36———-17.1 ± 21.27-1.9 ± 7.61——-3.9 ± 10.42
Day 126-5.7 ± 4.71———-8.7 ± 12.00-5.9 ± 11.81——-4.6 ± 11.30
SecondaryChange From Baseline in Pulse Rate (PR)

For participants enrolled in Group A cohorts, pulse rate was initially assessed every 2 hours for up to 6 hours after the end of infusion. Following implementation of Protocol Amendment 3, the assessment frequency was increased to hourly only for participants undergoing RHC.

Time frame:
Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (first 8 hours, second 8 hours, third 8 hours), Day 3 (first 8 hours, second 8 hours, third 8 hours), Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
Reported as:
Mean · beats per minute (bpm)
Change From Baseline in Pulse Rate (PR)
beats per minute (bpm)Group A: PlaceboGroup A: REGN5381 10 mgGroup A: REGN5381 30 mgGroup A: REGN5381 100 mgGroup A: REGN5381 300 mgGroup C: PlaceboGroup C: REGN5381 30 mgGroup C: REGN5381 100 mgGroup C: REGN5381 300 mg
Day 1 (2 hours post end of infusion)1.3 ± 5.85-5.3 ± 7.577.7 ± 8.33-3.5 ± 6.3811.8 ± 9.642.4 ± 5.098.0 ± 13.893.7 ± 0.586.5 ± 16.19
Day 1 (4 hours post end of infusion)-5.4 ± 6.00-1.3 ± 4.934.7 ± 2.89-0.7 ± 4.467.5 ± 8.812.7 ± 6.500.0 ± 5.574.7 ± 4.045.0 ± 9.94
Day 1 (6 hours post end of infusion)-1.7 ± 5.31-3.0 ± 8.194.3 ± 1.15-2.0 ± 3.8516.5 ± 10.282.9 ± 5.639.0 ± 14.735.3 ± 6.664.3 ± 9.24
Day 2 (first 8 hours)-4.4 ± 10.03-5.3 ± 11.0211.7 ± 6.66-4.5 ± 7.1217.0 ± 20.124.2 ± 9.801.3 ± 3.514.7 ± 6.511.4 ± 11.22
Day 2 (second 8 hours)-2.3 ± 13.57-11.0 ± 1.006.3 ± 4.93-2.2 ± 6.376.8 ± 25.554.1 ± 7.09-0.3 ± 3.513.3 ± 5.514.5 ± 8.17
Day 2 (third 8 hours)-0.9 ± 17.33-8.3 ± 4.514.0 ± 6.08-4.2 ± 5.569.3 ± 22.231.8 ± 6.39-1.3 ± 4.161.7 ± 7.511.3 ± 9.06
Day 3 (first 8 hours)0.9 ± 14.65-7.0 ± 10.441.0 ± 3.61-5.0 ± 7.322.3 ± 18.251.1 ± 8.05-1.3 ± 10.212.3 ± 8.74-1.7 ± 9.61
Day 3 (second 8 hours)10.5 ± 10.28——2.0 ± 8.19—1.9 ± 5.99-1.0 ± 6.24-0.3 ± 6.510.9 ± 9.04
Day 3 (third 8 hours)8.8 ± 6.95——-1.0 ± 7.55—0.2 ± 6.90-3.0 ± 4.580.3 ± 10.690.8 ± 6.21
Day 82.4 ± 10.420.0 ± 12.77-6.0 ± 10.82-2.5 ± 5.323.7 ± 6.431.9 ± 8.523.3 ± 2.52-0.3 ± 8.084.2 ± 10.15
Day 15-2.1 ± 16.71-1.7 ± 7.020.7 ± 7.51-4.7 ± 8.852.0 ± 8.893.5 ± 7.750.3 ± 3.51-2.3 ± 5.511.7 ± 11.81
Day 220.3 ± 16.78-3.0 ± 9.640.7 ± 8.33-4.7 ± 8.805.0 ± 16.094.1 ± 9.052.0 ± 12.00-0.7 ± 11.551.3 ± 5.68
Day 36-3.2 ± 14.69—-5.3 ± 5.13-1.3 ± 9.877.0 ± 23.644.7 ± 12.386.3 ± 11.06-1.0 ± 10.582.6 ± 13.71
Day 57-2.0 ± 11.87——2.2 ± 12.7512.0 ± 18.252.9 ± 12.09—3.3 ± 7.374.1 ± 12.87
Day 78-2.8 ± 10.13——-1.5 ± 11.794.7 ± 16.864.3 ± 12.47—0.7 ± 11.854.3 ± 9.85
Day 994.0 ± 18.38———6.7 ± 20.234.2 ± 11.40——7.2 ± 10.12
Day 1268.5 ± 17.68———13.3 ± 10.505.0 ± 15.16——7.3 ± 11.35
SecondaryFold Change From Baseline in N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP)

NT-proBNP is a clinical biomarker of heart failure. Coefficient of Variation for Fold Change from Baseline was computed as (standard deviation of the natural log-scale of the respective variable) \*100. Fold Change from Baseline is the ratio of Post-Baseline to Baseline, and it is assumed to follow a lognormal distribution. Per the study design, only some participants had a Day 4/Day 5 visit. Therefore, NT-proBNP data were not collected at this time point for all participants.

Time frame:
Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (24 hours post end of infusion), Day 3, Day 4, Day 5, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
Reported as:
Geometric mean · picograms per milliliter (pg/mL)
Fold Change From Baseline in N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP)
picograms per milliliter (pg/mL)Group A: PlaceboGroup A: REGN5381 10 mgGroup A: REGN5381 30 mgGroup A: REGN5381 100 mgGroup A: REGN5381 300 mgGroup C: PlaceboGroup C: REGN5381 30 mgGroup C: REGN5381 100 mgGroup C: REGN5381 300 mg
Day 1 (2 hours post end of infusion)1.09 ± 26.91.26 ± 30.81.30 ± 26.90.97 ± 14.80.91 ± 11.21.01 ± 12.41.05 ± 6.61.04 ± 18.20.94 ± 13.2
Day 1 (4 hours post end of infusion)1.13 ± 25.21.23 ± 28.41.36 ± 20.90.96 ± 12.70.95 ± 7.00.99 ± 18.30.97 ± 11.11.03 ± 19.00.89 ± 14.8
Day 1 (6 hours post end of infusion)1.19 ± 28.71.35 ± 32.61.39 ± 20.31.01 ± 14.40.98 ± 10.01.05 ± 19.81.04 ± 12.21.19 ± 23.70.91 ± 20.8
Day 2 (24 hours post end of infusion)1.12 ± 32.70.96 ± 18.31.12 ± 22.50.64 ± 39.21.13 ± 102.50.99 ± 23.80.79 ± 12.20.74 ± 37.70.63 ± 51.0
Day 30.66 ± 25.81.00 ± 18.61.09 ± 48.20.75 ± 48.61.32 ± 126.10.77 ± 35.60.66 ± 1.70.69 ± 11.90.68 ± 32.6
Day 40.98——0.76 ± 80.2—0.80 ± 37.20.72 ± 11.80.71 ± 15.70.89 ± 51.2
Day 50.73——0.81 ± 49.0—0.72 ± 67.50.97 ± 13.20.89 ± 21.50.99 ± 45.6
Day 81.06 ± 32.31.45 ± 36.73.01 ± 20.11.57 ± 44.71.23 ± 77.61.11 ± 38.31.02 ± 70.11.53 ± 39.81.40 ± 26.0
Day 150.96 ± 51.81.41 ± 50.62.92 ± 19.01.07 ± 62.31.42 ± 28.41.18 ± 43.32.19 ± 17.21.47 ± 51.01.43 ± 50.8
Day 221.00 ± 62.21.20 ± 55.01.92 ± 21.31.17 ± 56.50.80 ± 56.21.30 ± 43.51.90 ± 40.63.34 ± 150.21.29 ± 49.4
Day 360.80 ± 47.3—1.41 ± 68.00.98 ± 41.50.59 ± 23.31.13 ± 38.71.41 ± 32.22.66 ± 109.51.24 ± 58.0
Day 571.04 ± 93.2——0.76 ± 58.21.47 ± 54.31.13 ± 36.6—1.86 ± 86.31.19 ± 48.8
Day 780.63 ± 56.6——0.79 ± 44.20.46 ± 24.41.09 ± 40.3—1.75 ± 81.50.99 ± 38.4
Day 990.91 ± 37.2———0.42 ± 20.51.21 ± 42.5——0.90 ± 42.8
Day 1260.92 ± 52.2———0.63 ± 57.00.97 ± 37.7——1.03 ± 49.5
SecondaryPeak Concentration (Cmax) of REGN5381 in Serum
Time frame:
Up to Day 126
Reported as:
Mean · mg/L
Peak Concentration (Cmax) of REGN5381 in Serum
mg/LGroup A: REGN5381 10 mgGroup A: REGN5381 30 mgGroup A: REGN5381 100 mgGroup A: REGN5381 300 mgGroup C: REGN5381 30 mgGroup C: REGN5381 100 mgGroup C: REGN5381 300 mg
Peak Concentration (Cmax) of REGN5381 in Serum2.17 ± 0.2086.38 ± 1.3426.5 ± 6.0661.9 ± 14.87.37 ± 1.2922.7 ± 4.0168.3 ± 14.1
SecondaryArea Under the Concentration-time Curve From Time Zero to the Time of Last Measurable Concentration (AUClast) of REGN5381 in Serum
Time frame:
Up to Day 126
Reported as:
Mean · day*mg/L
Area Under the Concentration-time Curve From Time Zero to the Time of Last Measurable Concentration (AUClast) of REGN5381 in Serum
day*mg/LGroup A: REGN5381 10 mgGroup A: REGN5381 30 mgGroup A: REGN5381 100 mgGroup A: REGN5381 300 mgGroup C: REGN5381 30 mgGroup C: REGN5381 100 mgGroup C: REGN5381 300 mg
Area Under the Concentration-time Curve From Time Zero to the Time of Last Measurable Concentration (AUClast) of REGN5381 in Serum5.12 ± 0.28435.3 ± 7.99241 ± 29.2583 ± 34547.2 ± 16.6221 ± 38.5897 ± 149
SecondaryNumber of Participants With Anti-drug Antibodies (ADA)

The ADA status of each participant was classified as one of the following: * Negative - If all samples were found to be negative in the ADA assay * Pre-existing immunoreactivity - If the baseline sample was positive and all post baseline ADA titers were reported as less than 9-fold the baseline titer value * Treatment-Boosted Response * Treatment-Emergent Response

Time frame:
Baseline up to Day 126
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADA)
ParticipantsGroups A: PlaceboGroup A: REGN5381 100 mgGroup A: REGN5381 300 mgGroup C: PlaceboGroup C: REGN5381 30 mgGroup C: REGN5381 100 mgGroup C: REGN5381 300 mg
Negative463183311
Pre-existing Immunoreactivity0000000
Treatment-Boosted Response0000000
Treatment-Emergent Response0000001

Adverse events

Collected over From date of informed consent up to end of study (Day 126). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A: Placebo0/7 (0%)0/7 (0%)3/7 (42.9%)
Group A: REGN5381 10 mg0/3 (0%)0/3 (0%)1/3 (33.3%)
Group A: REGN5381 30 mg0/3 (0%)0/3 (0%)1/3 (33.3%)
Group A: REGN5381 100 mg0/6 (0%)0/6 (0%)1/6 (16.7%)
Group A: REGN5381 300 mg1/4 (25%)2/4 (50%)3/4 (75%)
Group C: Placebo0/18 (0%)0/18 (0%)3/18 (16.7%)
Group C: REGN5381 30 mg0/3 (0%)0/3 (0%)1/3 (33.3%)
Group C: REGN5381 100 mg0/3 (0%)0/3 (0%)2/3 (66.7%)
Group C: REGN5381 300 mg0/12 (0%)1/12 (8.3%)4/12 (33.3%)
Most frequent serious events
Most frequent serious events
EventGroup A: PlaceboGroup A: REGN5381 10 mgGroup A: REGN5381 30 mgGroup A: REGN5381 100 mgGroup A: REGN5381 300 mgGroup C: PlaceboGroup C: REGN5381 30 mgGroup C: REGN5381 100 mgGroup C: REGN5381 300 mg
Cardiac failureCardiac disorders0/70/30/30/61/40/180/30/30/12
Ischaemic hepatitisHepatobiliary disorders0/70/30/30/61/40/180/30/30/12
Respiratory tract procedural complicationInjury, poisoning and procedural complications0/70/30/30/60/40/180/30/31/12
Most frequent other events
Showing 10 of 19
Most frequent other events
EventGroup A: PlaceboGroup A: REGN5381 10 mgGroup A: REGN5381 30 mgGroup A: REGN5381 100 mgGroup A: REGN5381 300 mgGroup C: PlaceboGroup C: REGN5381 30 mgGroup C: REGN5381 100 mgGroup C: REGN5381 300 mg
Abdominal pain upperGastrointestinal disorders0/70/30/30/60/40/181/30/30/12
Back painMusculoskeletal and connective tissue disorders0/70/30/30/61/41/180/31/31/12
Atrial fibrillationCardiac disorders0/70/30/30/60/40/180/31/30/12
Catheter site discomfortGeneral disorders0/70/31/30/60/40/181/30/30/12
Non-cardiac chest painGeneral disorders0/71/30/30/60/40/180/30/30/12
Infusion related reactionInjury, poisoning and procedural complications0/70/31/30/60/40/180/30/30/12
Ventricular extrasystolesCardiac disorders2/70/30/30/60/40/180/30/30/12
NauseaGastrointestinal disorders0/70/30/30/61/40/180/30/30/12
VomitingGastrointestinal disorders0/70/30/30/61/40/180/30/30/12
COVID-19Infections and infestations0/70/30/30/61/40/180/30/30/12

Baseline characteristics

Safety Analysis Set (SAF): All randomized participants who received any study drug.

Age, Customized
Age, Customized(Participants)Group A: PlaceboGroup A: REGN5381 10 mgGroup A: REGN5381 30 mgGroup A: REGN5381 100 mgGroup A: REGN5381 300 mgGroup C: PlaceboGroup C: REGN5381 30 mgGroup C: REGN5381 100 mgGroup C: REGN5381 300 mgTotal
< 18 years0000000000
≥ 18 to < 45 years0002000002
≥ 45 to < 65 years53334702532
≥ 65 to < 75 years200101131624
≥ 75 years0000000011
Sex: Female, Male
Sex: Female, Male(Participants)Group A: PlaceboGroup A: REGN5381 10 mgGroup A: REGN5381 30 mgGroup A: REGN5381 100 mgGroup A: REGN5381 300 mgGroup C: PlaceboGroup C: REGN5381 30 mgGroup C: REGN5381 100 mgGroup C: REGN5381 300 mgTotal
Female10111500413
Male632531333846
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group A: PlaceboGroup A: REGN5381 10 mgGroup A: REGN5381 30 mgGroup A: REGN5381 100 mgGroup A: REGN5381 300 mgGroup C: PlaceboGroup C: REGN5381 30 mgGroup C: REGN5381 100 mgGroup C: REGN5381 300 mgTotal
Hispanic or Latino0000000000
Not Hispanic or Latino7336418331259
Unknown or Not Reported0000000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group A: PlaceboGroup A: REGN5381 10 mgGroup A: REGN5381 30 mgGroup A: REGN5381 100 mgGroup A: REGN5381 300 mgGroup C: PlaceboGroup C: REGN5381 30 mgGroup C: REGN5381 100 mgGroup C: REGN5381 300 mgTotal
American Indian or Alaska Native0000000000
Asian0000000000
Native Hawaiian or Other Pacific Islander0000000000
Black or African American0000000000
White7336418331259
Unknown or Not Reported0000000000
08

Study locations

1 site
  • ARENSIA Exploratory Medicine at the Republican Clinical Hospital
    Chisinau, 2025, Moldova
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Jun 2025, 35 months.

Results were first posted in Sep 2026, 1 year 3 months after primary completion.

Of 73 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 35 months is above that.

Counting every sponsor, half of 184 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2022
First posted
Apr 29, 2022
StartActual
Jun 30, 2022
Primary completionActual
Jun 2, 2025
CompletionActual
Jun 2, 2025
Results first posted
Sep 29, 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 29, 2026
Sites
1 site added, 1 site removed — first site in Moldova; no longer in Moldova, Republic of
Show site
  • ARENSIA Exploratory Medicine at the Republican Clinical Hospital · Chisinau, Moldova
Show 1 removed
  • ARENSIA Exploratory Medicine at the Republican Clinical Hospital · Chișinău, Moldova, Republic of
Sep 29, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedIncidence and severityNumber of treatmentParticipants With Treatment-emergent adverse eventsAdverse Events (TEAEs)Time frame: Through the end-of-study (EOS) visit up to 126 days post-dose → From first dose (Day 1) up to end of study (Day 126)
Sep 29, 2026
Documents
Secondary outcomes
13 edited, 1 added
What changed in the outcomes
  • EditedChange from baselineFrom Baseline in pulmonary capillary wedge pressurePulmonary Capillary Wedge Pressure (PCWP)Time frame: Over 6 hours post-dose administration → Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion)
  • EditedChange from baseline right atrial pressureFrom Baseline in Central Venous Pressure (RAPCVP)Time frame: Over 6 hours post-dose administration → Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)
  • EditedChange from baseline cardiac outputFrom Baseline in Invasive Cardiac Output (CO)Time frame: Over 6 hours post-dose administration → Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)
  • EditedChange from baseline systemic vascular resistanceFrom Baseline in Systemic Vascular Resistance (SVR)Time frame: Over 6 hours post-dose administration → Baseline, Day 1 (0 hours, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, and 6 hours post end of infusion)
  • EditedChange from baseline mean pulmonary artery pressureFrom Baseline in Mean Pulmonary Artery Pressure (mPAP)Time frame: Over 6 hours post-dose administration → Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)
  • EditedChange from baseline pulmonary vascular resistanceFrom Baseline in Pulmonary Vascular Resistance (PVR)Time frame: Over 6 hours post-dose administration → Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion)
  • EditedChange from baselineFrom Baseline in systolic blood pressureSystolic Blood Pressure (SBP)Time frame: Over the first 6 hours, 24 hours post-dose administration (day 1), through the EOS visit up to 126 days post-dose → Baseline, Day 1 (0, 1, 2, 3, 4, 5, 6, 7, 8 hours post end of infusion), Day 2 to Day 5 every 8 hours, Day 6 first 8 hours, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
  • EditedChange from baselineFrom Baseline in diastolic blood pressureDiastolic Blood Pressure (DBP)Time frame: Over the first 6 hours, 24 hours post-dose administration (day 1), through the EOS visit up to 126 days post-dose → Baseline, Day 1 (0, 1, 2, 3, 4, 5, 6, 7, 8 hours post end of infusion), Day 2 to Day 5 every 8 hours, Day 6 first 8 hours, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
  • EditedChange from baselineFrom Baseline in mean arterial pressureMean Arterial Pressure (MAP)Time frame: Over the first 6 hours, 24 hours post-dose administration (day 1), through the EOS visit up to 126 days post-dose → Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (first 8 hours, second 8 hours, third 8 hours), Day 3 (first 8 hours, second 8 hours, third 8 hours), Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
  • EditedChange from baselineFrom Baseline in pulse ratePulse Rate (PR)Time frame: Over the first 6 hours, 24 hours post-dose administration (day 1), through the EOS visit up to 126 days post-dose → Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (first 8 hours, second 8 hours, third 8 hours), Day 3 (first 8 hours, second 8 hours, third 8 hours), Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
  • EditedFold Change from baselineFrom Baseline in N-terminal proPro-brain natriuretic peptideBrain Natriuretic Peptide (NT-proBNP)Time frame: To 6 hours, 24 hours post-dose administration (day 1), through the EOS visit up to 126 days post-dose → Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (24 hours post end of infusion), Day 3, Day 4, Day 5, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
  • EditedConcentrationsPeak Concentration (Cmax) of REGN5381 in serumSerumTime frame: Through the EOS visit, up to 126 days post-dose → Up to Day 126
  • EditedImmunogenicity, as measured by antiNumber of Participants With Anti-drug antibodiesAntibodies (ADA) to REGN5381Time frame: Through the EOS visit, up to 126 days post-dose → Baseline up to Day 126
  • AddedArea Under the Concentration-time Curve From Time Zero to the Time of Last Measurable Concentration (AUClast) of REGN5381 in SerumTime frame: Up to Day 126
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Results posted
    1 site added, 1 site removed — first site in Moldova; no longer in Moldova, Republic of
    Show site
    • ARENSIA Exploratory Medicine at the Republican Clinical Hospital · Chisinau, Moldova
    Show 1 removed
    • ARENSIA Exploratory Medicine at the Republican Clinical Hospital · Chișinău, Moldova, Republic of
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedIncidence and severityNumber of treatmentParticipants With Treatment-emergent adverse eventsAdverse Events (TEAEs)Time frame: Through the end-of-study (EOS) visit up to 126 days post-dose → From first dose (Day 1) up to end of study (Day 126)
    Secondary outcomes 13 edited, 1 added
    What changed in the outcomes
    • EditedChange from baselineFrom Baseline in pulmonary capillary wedge pressurePulmonary Capillary Wedge Pressure (PCWP)Time frame: Over 6 hours post-dose administration → Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion)
    • EditedChange from baseline right atrial pressureFrom Baseline in Central Venous Pressure (RAPCVP)Time frame: Over 6 hours post-dose administration → Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)
    • EditedChange from baseline cardiac outputFrom Baseline in Invasive Cardiac Output (CO)Time frame: Over 6 hours post-dose administration → Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)
    • EditedChange from baseline systemic vascular resistanceFrom Baseline in Systemic Vascular Resistance (SVR)Time frame: Over 6 hours post-dose administration → Baseline, Day 1 (0 hours, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, and 6 hours post end of infusion)
    • EditedChange from baseline mean pulmonary artery pressureFrom Baseline in Mean Pulmonary Artery Pressure (mPAP)Time frame: Over 6 hours post-dose administration → Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)
    • EditedChange from baseline pulmonary vascular resistanceFrom Baseline in Pulmonary Vascular Resistance (PVR)Time frame: Over 6 hours post-dose administration → Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion)
    • EditedChange from baselineFrom Baseline in systolic blood pressureSystolic Blood Pressure (SBP)Time frame: Over the first 6 hours, 24 hours post-dose administration (day 1), through the EOS visit up to 126 days post-dose → Baseline, Day 1 (0, 1, 2, 3, 4, 5, 6, 7, 8 hours post end of infusion), Day 2 to Day 5 every 8 hours, Day 6 first 8 hours, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
    • EditedChange from baselineFrom Baseline in diastolic blood pressureDiastolic Blood Pressure (DBP)Time frame: Over the first 6 hours, 24 hours post-dose administration (day 1), through the EOS visit up to 126 days post-dose → Baseline, Day 1 (0, 1, 2, 3, 4, 5, 6, 7, 8 hours post end of infusion), Day 2 to Day 5 every 8 hours, Day 6 first 8 hours, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
    • EditedChange from baselineFrom Baseline in mean arterial pressureMean Arterial Pressure (MAP)Time frame: Over the first 6 hours, 24 hours post-dose administration (day 1), through the EOS visit up to 126 days post-dose → Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (first 8 hours, second 8 hours, third 8 hours), Day 3 (first 8 hours, second 8 hours, third 8 hours), Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
    • EditedChange from baselineFrom Baseline in pulse ratePulse Rate (PR)Time frame: Over the first 6 hours, 24 hours post-dose administration (day 1), through the EOS visit up to 126 days post-dose → Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (first 8 hours, second 8 hours, third 8 hours), Day 3 (first 8 hours, second 8 hours, third 8 hours), Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
    • EditedFold Change from baselineFrom Baseline in N-terminal proPro-brain natriuretic peptideBrain Natriuretic Peptide (NT-proBNP)Time frame: To 6 hours, 24 hours post-dose administration (day 1), through the EOS visit up to 126 days post-dose → Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (24 hours post end of infusion), Day 3, Day 4, Day 5, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
    • EditedConcentrationsPeak Concentration (Cmax) of REGN5381 in serumSerumTime frame: Through the EOS visit, up to 126 days post-dose → Up to Day 126
    • EditedImmunogenicity, as measured by antiNumber of Participants With Anti-drug antibodiesAntibodies (ADA) to REGN5381Time frame: Through the EOS visit, up to 126 days post-dose → Baseline up to Day 126
    • AddedArea Under the Concentration-time Curve From Time Zero to the Time of Last Measurable Concentration (AUClast) of REGN5381 in SerumTime frame: Up to Day 126
    + 3 other changes: identifiers, verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05353166
Responsible party
Sponsor
First posted
Apr 29, 2022
Start date
Jun 30, 2022
Primary completion
Jun 2, 2025
Completion
Jun 2, 2025
Results posted
Sep 29, 2026
Last update
Sep 29, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vixticibart

Start the discussion